BACKGROUND:Extensive extracellular matrix (ECM) remodeling is a hallmark of metastatic pancreatic ductal adenocarcinoma (mPDA). We investigated fragments of collagen types III (C3M, PRO-C3), VI (PRO-C6), and VIII (C8-C), and versican (VCANM) in plasma as biomarkers for predicting progression-free survival (PFS) and overall survival (OS) in patients with mPDA treated with pegvorhyaluronidase alfa, a biologic that degrades the ECM component hyaluronan (HA), in a randomized phase 2 study (HALO109-202). METHODS:HALO109-202 comprised a discovery cohort (Stage 1, n = 94) and a validation cohort (Stage 2, n = 95). Plasma ECM biomarkers were analyzed by ELISAs. Univariate Cox regression analysis and Kaplan-Meier plots evaluated predictive associations between biomarkers, PFS and OS in patients treated with pegvorhyaluronidase alfa plus nab-paclitaxel/gemcitabine (PAG) versus nab-paclitaxel/gemcitabine (AG) alone. RESULTS:PFS was improved with PAG vs. AG in Stage 1 patients with high C3M/PRO-C3 ratio (median cut-off): median PFS (mPFS) 8.0 vs. 5.3 months, P = 0.031; HR = 0.40; 95% CI 0.17-0.92). High C3M/PRO-C3 ratio was validated in Stage 2 patients by predicting a PFS benefit of PAG vs. AG (mPFS: 8.8 vs. 3.4 months, P = 0.046; HR = 0.46; 95% CI 0.21-0.98). OS was also improved in patients with high C3M/PRO-C3 ratio treated with PAG vs. AG (mOS 13.8 vs 8.5 months, P = 0.009; HR = 0.35; 95% CI 0.16-0.77). Interestingly, high C3M/PRO-C3 ratio predicted for a PFS benefit to PAG vs. AG both in patients with HA-low tumors (HR = 0.36; 95% CI 0.17-0.79) and HA-high tumors (HR = 0.20; 95% CI 0.06-0.69). CONCLUSIONS: The C3M/PRO-C3 ratio measuring type III collagen turnover in plasma has potential as a blood-based predictive biomarker in patients with mPDA and provides additional value to a HA biopsy when applied for patient selection. TRIAL REGISTRATION: NCT01839487. Registered 25 April 2016.
RCT Entities:
BACKGROUND: Extensive extracellular matrix (ECM) remodeling is a hallmark of metastatic pancreatic ductal adenocarcinoma (mPDA). We investigated fragments of collagen types III (C3M, PRO-C3), VI (PRO-C6), and VIII (C8-C), and versican (VCANM) in plasma as biomarkers for predicting progression-free survival (PFS) and overall survival (OS) in patients with mPDA treated with pegvorhyaluronidase alfa, a biologic that degrades the ECM component hyaluronan (HA), in a randomized phase 2 study (HALO109-202). METHODS:HALO109-202 comprised a discovery cohort (Stage 1, n = 94) and a validation cohort (Stage 2, n = 95). Plasma ECM biomarkers were analyzed by ELISAs. Univariate Cox regression analysis and Kaplan-Meier plots evaluated predictive associations between biomarkers, PFS and OS in patients treated with pegvorhyaluronidase alfa plus nab-paclitaxel/gemcitabine (PAG) versus nab-paclitaxel/gemcitabine (AG) alone. RESULTS: PFS was improved with PAG vs. AG in Stage 1 patients with high C3M/PRO-C3 ratio (median cut-off): median PFS (mPFS) 8.0 vs. 5.3 months, P = 0.031; HR = 0.40; 95% CI 0.17-0.92). High C3M/PRO-C3 ratio was validated in Stage 2 patients by predicting a PFS benefit of PAG vs. AG (mPFS: 8.8 vs. 3.4 months, P = 0.046; HR = 0.46; 95% CI 0.21-0.98). OS was also improved in patients with high C3M/PRO-C3 ratio treated with PAG vs. AG (mOS 13.8 vs 8.5 months, P = 0.009; HR = 0.35; 95% CI 0.16-0.77). Interestingly, high C3M/PRO-C3 ratio predicted for a PFS benefit to PAG vs. AG both in patients with HA-low tumors (HR = 0.36; 95% CI 0.17-0.79) and HA-high tumors (HR = 0.20; 95% CI 0.06-0.69). CONCLUSIONS: The C3M/PRO-C3 ratio measuring type III collagen turnover in plasma has potential as a blood-based predictive biomarker in patients with mPDA and provides additional value to a HA biopsy when applied for patient selection. TRIAL REGISTRATION: NCT01839487. Registered 25 April 2016.
Authors: Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani Journal: Cancer Cell Date: 2012-03-20 Impact factor: 31.743
Authors: Anastasia V Suhovskih; Svetlana V Aidagulova; Vladimir I Kashuba; Elvira V Grigorieva Journal: Cell Tissue Res Date: 2015-02-26 Impact factor: 5.249
Authors: Natasha Barascuk; Federica Genovese; Lise Larsen; Inger Byrjalsen; Qinlong Zheng; Shu Sun; Susanne Hosbond; Tina S Poulsen; Axel Diederichsen; Jesper M Jensen; Hans Mickley; Thomas C Register; Lars M Rasmussen; Diana J Leeming; Claus Christiansen; Morten A Karsdal Journal: Int J Clin Exp Med Date: 2013-03-21
Authors: Marvin Schober; Ralf Jesenofsky; Ralf Faissner; Cornelius Weidenauer; Wolfgang Hagmann; Patrick Michl; Rainer L Heuchel; Stephan L Haas; J-Matthias Löhr Journal: Cancers (Basel) Date: 2014-10-21 Impact factor: 6.639
Authors: Christina Jensen; Daniel Hargbøl Madsen; Morten Hansen; Henrik Schmidt; Inge Marie Svane; Morten Asser Karsdal; Nicholas Willumsen Journal: J Immunother Cancer Date: 2018-12-19 Impact factor: 13.751
Authors: Neel I Nissen; Astrid Z Johansen; Inna Chen; Julia S Johansen; Rasmus S Pedersen; Carsten P Hansen; Morten A Karsdal; Nicholas Willumsen Journal: Cancers (Basel) Date: 2022-02-06 Impact factor: 6.639
Authors: M Ines Pascoal Ramos; Linjie Tian; Dallas Flies; Linde Meyaard; Emma J de Ruiter; Chang Song; Ana Paucarmayta; Akashdip Singh; Eline Elshof; Saskia V Vijver; Jahangheer Shaik; Jason Bosiacki; Zachary Cusumano; Christina Jensen; Nicholas Willumsen; Morten A Karsdal; Linda Liu; Sol Langermann; Stefan Willems Journal: Elife Date: 2021-06-14 Impact factor: 8.140
Authors: Nicholas Willumsen; Christina Jensen; George Green; Neel I Nissen; Jaclyn Neely; David M Nelson; Rasmus S Pedersen; Peder Frederiksen; Inna M Chen; Mogens K Boisen; Astrid Z Johansen; Daniel H Madsen; Inge Marie Svane; Allan Lipton; Kim Leitzel; Suhail M Ali; Janine T Erler; Daan P Hurkmans; Ron H J Mathijssen; Joachim Aerts; Mohammed Eslam; Jacob George; Claus Christiansen; Mina J Bissel; Morten A Karsdal Journal: Cell Mol Life Sci Date: 2022-03-25 Impact factor: 9.207